Your browser doesn't support javascript.
Ramadan fasting: recommendations for patients with cardiovascular disease.
Akhtar, Abid Mohammed; Ghouri, Nazim; Chahal, C Anwar A; Patel, Riyaz; Ricci, Fabrizio; Sattar, Naveed; Waqar, Salman; Khanji, Mohammed Yunus.
  • Akhtar AM; Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, London, UK m.khanji@qmul.ac.uk mohammed.akhtar@nhs.net.
  • Ghouri N; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
  • Chahal CAA; Department of Diabetes and Endocrinology, Queen Elizabeth University Hospital, Glasgow, UK.
  • Patel R; Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, London, UK.
  • Ricci F; Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
  • Sattar N; Department of Medicine, Division of Cardiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Waqar S; Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, London, UK.
  • Khanji MY; Institute of Cardiovascular Sciences, University College London, London, UK.
Heart ; 108(4): 258-265, 2022 02.
Article in English | MEDLINE | ID: covidwho-2137872
ABSTRACT
Ramadan fasting is observed by most of the 1.8 billion Muslims around the world. It lasts for 1 month per the lunar calendar year and is the abstention from any food and drink from dawn to sunset. While recommendations on 'safe' fasting exist for patients with some chronic conditions, such as diabetes mellitus, guidance for patients with cardiovascular disease is lacking. We reviewed the literature to help healthcare professionals educate, discuss and manage patients with cardiovascular conditions, who are considering fasting. Studies on the safety of Ramadan fasting in patients with cardiac disease are sparse, observational, of small sample size and have short follow-up. Using expert consensus and a recognised framework, we risk stratified patients into 'low or moderate risk', for example, stable angina or non-severe heart failure; 'high risk', for example, poorly controlled arrhythmias or recent myocardial infarction; and 'very high risk', for example, advanced heart failure. The 'low-moderate risk' group may fast, provided their medications and clinical conditions allow. The 'high' or 'very high risk' groups should not fast and may consider safe alternatives such as non-consecutive fasts or fasting shorter days, for example, during winter. All patients who are fasting should be educated before Ramadan on their risk and management (including the risk of dehydration, fluid overload and terminating the fast if they become unwell) and reviewed after Ramadan to reassess their risk status and condition. Further studies to clarify the benefits and risks of fasting on the cardiovascular system in patients with different cardiovascular conditions should help refine these recommendations.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Diseases / Heart Failure Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Heart Journal subject: Cardiology Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Diseases / Heart Failure Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Heart Journal subject: Cardiology Year: 2022 Document Type: Article